Producing proteins is a time-consuming, painstaking process, particularly from mammalian cell lines, and the investment required in terms of time, expertise, cost and infrastructure prevents most researchers from taking on the task in their own laboratories. Obtaining proteins from commercial sources is prohibitively expensive for scientists on tight budgets.
“Having this service close at hand has been fantastic for my research,” says EPFL researcher Patrick Fraering. “In my field [neurodegenerative disease] developments move very quickly. In order to stay competitive internationally, I need quick access to proteins from mammalian cell lines, and there is no way I could produce them with this level of efficiency myself.”
Building on the demonstrated benefits of the facility to EPFL researchers, the School of Life Sciences decided to formalize the facility and extend the service to scientists doing basic research outside EPFL. This will allow the Facility to recoup some costs and has the added benefit of stimulating collaborations and cross-institutional exchange. It’s cost-effective for users, because even though they will be charged a fee for the proteins, it’s far below what they would pay for commercial proteins and roughly a quarter of what it would cost them to produce the proteins themselves. And with a tight turnaround time – the facility can produce proteins from mammalian cells in less than four weeks – researchers can quickly follow up on promising leads. Once the development of a protein reaches a clinical or commercial stage, production will be transferred to a commercial facility.
The facility also provides training in gene transfer techniques and cultivation of cells in suspension. As facility manager David Hacker points out, “by offering guidance and training, we can enhance the chance that researchers’ projects will succeed.”
Recombinant proteins - From a Swiss past to a Swiss future?
In 1978, Swiss scientist Werner Arber shared the Nobel prize in medicine with Americans Daniel Nathans and Hamilton Smith for discovering a technique to incorporate non-native DNA into living cells. The re-combined, or “recombinant”, DNA holds instructions for the cell to produce the non-native protein which can subsequently be extracted and purified.
The 25,000 genes that make up human genome hold the blueprints for the manufacture of anywhere from 250,000 - 1 million proteins. But only about 50 of these proteins are understood well enough to be used in therapeutic applications. Insulin, EPO, and herceptin, an antibody used in breast cancer treatment, are a few better-known examples.
The global market for antibodies, proteins, and hormones produced using the recombinant DNA technique is currently on the order of $20 billion. Global demand for insulin is expected to rise by 14% annually. Most biomedical researchers agree that the therapeutic and market potential of recombinant proteins is not even close to being fully exploited. “It’s very important that we take advantage of the opportunities available in recombinant proteins,” notes Wurm. “A lack of opportunity for exploring this potential will diminish the European contribution to biomedical research considerably, and we’re likely to get left behind in the market as well.”
“If we want to jump-start biomedical research on proteins in Europe, the path from idea to innovation needs to be optimized,” urges Wurm. “With this facility, EPFL is in a key position to help make this happen.”
Mary Parlange | alfa
How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH
A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology